EGFR and colorectal carcinoma: In 2015, Siravegna et al. mentioned that the genome of CRC adapts dynamically to pulsatile drug schedules provide rationale for additional lines of therapy for patients who benefit from an initial challenge with anti-EGFR antibodies [51].